Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8483677 | 0.81 | CNR1 (0.35) | CNR1CNR2PTGS1PTGS2 | |
| SCHEMBL6955830 | 0.79 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL6955837 | 0.79 | PTGS1 (0.33) | CNR1CNR2PTGS1PTGS2 | |
| SCHEMBL1929209 | 0.72 | CA1 (0.44) | PTGS1PTGS2 | |
| SCHEMBL6966970 | 0.71 | CA1 (0.43) | PTGS1PTGS2 | |
| SCHEMBL6960419 | 0.71 | CA1 (0.43) | PTGS1PTGS2 | |
| SCHEMBL6959668 | 0.70 | PTGS1 (0.47) | PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL6959143 | 0.70 | PPARG (0.39) | CNR1CNR2 | |
| SCHEMBL1929518 | 0.69 | CA1 (0.47) | PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL6964007 | 0.69 | PPARA (0.38) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-6166216-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6156748-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | CNR1 586/4885CNR2 386/4885PTGS1 380/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | CNR1 586/4885CNR2 386/4885PTGS1 380/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | CNR1 624/4885CNR2 415/4885PTGS1 453/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | CNR1 624/4885CNR2 415/4885PTGS1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.